# Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

> **NCT01857869** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 64 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GSK257049 Dosage 1
- **BIOLOGICAL:** GSK257049 Dosage 2
- **PROCEDURE:** Sporozoite-infected mosquitoes challenge

## Key facts

- **NCT ID:** NCT01857869
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-20
- **Primary completion:** 2014-03-24
- **Final completion:** 2014-12-16
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857869, "Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01857869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*